Results 111 to 120 of about 52,949 (209)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation

, 2017
Nishant Patel,1 Pingping Wu,2 Haijun Zhang1 1Department of Oncology, Zhongda Hospital, Medical School, Southeast University, 2Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, People’s Republic of China Objectives: Gefitinib, a ...
Patel N, Wu P, Zhang H
core  

Table_1_ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC.DOC

, 2018
Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable ...
Yi Dai (47974), Hongbo Zhao (539923), Lanxiang Wu (5989886), Honghao Zhou (405068), Jingjing Shi (407360), Yutang Huang (5989883)   +5 more
core   +1 more source

Synthesis of gefitinib

, 2005
Aim: To develop the general route for the synthesis of gefitinib. Method: 2-Amino-4, 5-dimethoxybenzoic acid was cyclized, monodemethylated, acetylated, ammoniated and chlorinated to obtain the target compound.
Zou, Ai Feng, Chen, Guo Hua, Ren, Jin Shan, Shi, Tao, Jin, Bo   +4 more
core  

Inclusion Complexation of Gefitinib with Cyclodextrins [PDF]

, 2008
Gefitinib, a very slightly soluble new drug, is used in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have previously received chemotherapy.
Lee, Yann-Huei
core  

Gefitinib in Non Small Cell Lung Cancer

, 2011
Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/
Francesco Perrone, Agnese Montanino, Raffaele Costanzo, Alessandro Morabito, Nicola Normanno, Pasqualina Giordano, Jane Bryce, Gianfranco De Feo, Gennaro Daniele, Claudia Sandomenico, Gaetano Rocco, Maria Carmela Piccirillo, Massimo Di Maio, Guido Carillio   +13 more
core   +1 more source

Detection of somatic mutations in EGFR and KRAS genes in formalin-fixed paraffin-embedded specimens from Non-Small Cell Lung Cancer Patients [PDF]

, 2012
Non-small-cell lung cancer (NSCLC) accounts for 80% of lung cancer and has a 5 year survival rate of just 15%. Recently, tyrosine kinase inhibitors (TKIs) have been found to give dramatic therapeutic benefit to some patients increasing both their overall
Law, Tania Alice
core  

Effects of paclitaxel and gefitinib on the proliferation and cell cycle of human lung adenocarcinoma cell SPC-A1

Chinese Journal of Lung Cancer, 2008
Background and objective Previous clinical trials showed that there was no clinical benefit in the treatment of advanced non-small cell lung cancer when chemotherapy combined with gefitinib.
Gang JIA, Weimin ZHANG, Juan ZHOU, Zhixia ZHOU   +3 more
doaj  

Engineering a Redox-Responsive Bimolecular Prodrug for Targeted Gastric Cancer Combination Therapy: Design, Synthesis, and In Vivo Evaluation. [PDF]

Antioxidants (Basel)
Wang C, Xiu Y, Zhang Y, Xu J, Wang Y, Xing D.   +5 more
europepmc   +1 more source

Time-Resolved Network Entropy Analysis Identifies a CTNND1-VAV3 Subnetwork in Gefitinib-Resistant NSCLC. [PDF]

Int J Mol Sci
Tsakona DC, Papanikolaou NA.
europepmc   +1 more source

A systematic review and network meta-analysis of first-line EGFR-TKI-based combination strategies for EGFR-mutant non-small cell lung cancer with brain metastases. [PDF]

Sci Rep
Ma J, Zhao W, Guo W, Li Z, Lu X, Yang X, Jia C, Zhou Q, Jiang J.   +8 more
europepmc   +1 more source